Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration‐Resistant Prostate Cancer Treatment With Eribulin

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 7, 2015-08 ,pp. : 374-385

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment

By Badrising Sushil   van der Noort Vincent   van Oort Inge M.   van den Berg H. Pieter   Los Maartje   Hamberg Paul   Coenen Jules L.   van den Eertwegh Alfons J. M.   de Jong Igle J.   Kerver Emile D.   van Tinteren Harm   Bergman Andries M.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

Blackwell Publishing

Access to resources Recommend Favorite

Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer

By Twiddy Alexis   Leon Carlos   Wasan Kishor  

Pharmaceutical Research, Vol. 28, Iss. 3, 2011-03 ,pp. : 423-437

Springer Publishing Company

Access to resources Recommend Favorite

Sipuleucel-T: In Metastatic Castration-Resistant Prostate Cancer

By Plosker Greg L.  

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 101-108

Adis International

Access to resources Recommend Favorite

Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer

By Yang Lily P.H.  

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2067-2077

Adis International

Access to resources Recommend Favorite